Lipid profile abnormalities in newly diagnosed type 2 diabetics: a cross-sectional study
DOI:
https://doi.org/10.18203/2349-3933.ijam20193620Keywords:
Cardiovascular disease, Hypertriglyceridemia, Type 2 diabetes, Lipid profileAbstract
Background: India is fast becoming the diabetes capital of the World. A direct atherogenic effect of triglyceride rich particles has been noted. This study assesses the lipid profile abnormalities in newly diagnosed type 2 diabetes mellitus. Since dyslipidemia is a risk factor for cardiovascular disease, such assessment will enable better recognition, prevention and management of cardiovascular mortality and morbidity.
Methods: The study was conducted over a period of one year at a tertiary care hospital in South India. A cross-sectional study of 100 newly diagnosed type 2 diabetics in a rural South-Indian population was done.
Results: In our study, 55 (55%) participants had high triglycerides and 45 (45%) had normal triglycerides. Among the 55 participants with abnormal triglycerides, 34% had borderline high levels (150-199mg/dl), 18% had high levels (200-499 mg/dl) and 3% participants had very high triglycerides (≥500 mg/dl). 26% male and 29% female participants had above normal triglyceride levels. In our study, 25% had borderline high cholesterol levels and 5% had high total Cholesterol. 39% of participants had near optimal levels of LDL, 19% had borderline high levels of LDL, 7% had high levels of LDL and 4% had very high levels of LDL. Significantly higher levels of triglycerides and LDL were noted.
Conclusions: Deranged lipid profiles are quite prevalent in type 2 diabetics with females having higher triglyceride levels. Recognition of such elevated triglyceride levels in even newly diagnosed type 2 diabetics will help in better prevention of associated cardiovascular disease.
References
Ebbel B. The papyrus Ebers. Copenhagen and Oxford: Oxford University Press; 1937;115.
Mahato RV, Gyawali P, Raut PP, Regmi P, Kelanand PS, Dipendra RP, et al. Association between glycaemic control and serum lipid profile in type 2 diabetic patients: glycated haemoglobin as a dual biomarker. Biomed Res. 2011;22(3):375-80.
Taskinen MR. Diabetic dyslipidemia. Atheroscler Suppl. 2002;3(1):47-51.
Ronald M. Krauss. Lipids and Lipoproteins in Patients with Type 2 Diabetes. Diabetes Care Jun 2004;22(6)1496-504.
Hokanson JE, Austin MA: Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc. Risk. 1996;3(2):213-9.
Keating GM, Croom KF, Fenofibrate: a review of its use in primary dyslipidemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs. 2007,67(1):121-53.
Deepa M, Farooq S, Datta M, Deepa R, Mohan V. Prevalence of metabolic syndrome using WHO, ATPIII and IDF definitions in Asian Indians: The Chennai Urban Rural Epidemiology Study. Diabetes Metab Res Rev. 2007;23(2):127-34.
Nahar S, Rahman MZ, Ullah M, Debnath BC, Sultana N, Farhad CMRQ. Prevalence of Metabolic Syndrome in Newly diagnosed Type 2 Diabetes Mellitus. Cardiovase J. 2011;4(1):17-25.
Bharadwaj S, Misra A, Misra R, Goel K, Bhatt SP, Rastogi K et al. High Prevalence of abdominal, intraabdominal and subcutaneous adiposity and clustering of risk factors among urban asian Indians in north India. PLos One. 2011;6(9):e24362
Joshi SR, Anjana RM, Deepa M, Pradeepa R, Bhansali A, DHandania VK. Prevalence of dyslipidemia in urban and rural India. The ICMR-INDIAB Study. PLoS ONE. 2014;9(5):e96808.
Karadag MK, Akbulut M. Low HDL levels as the most common metabolic syndrome risk factor in heart failure. Int Heart J. 2009 Sep;50(5):571-80.
Ogbera AO. Prevalence and gender distribution of the metabolic syndrome. Diabetol Metab Syndr.2010;2(1):1.
